Tocilizumab in Active Moderate-severe Graves' Orbitopathy
Status:
Recruiting
Trial end date:
2023-12-18
Target enrollment:
Participant gender:
Summary
To treat patientis with active moderate-severe GO with the anti-IL6 receptor monoclonal
antibody tocilizubam with the purpose of assesing the efficacy of therapy on active GO and on
the proportion of patiens with inactivation and reactivation of disease (Primary Objective)
Effect of therapy on disease progression, improvement of QoL, the degree of residual disease
after the inflammatory phase and safety of treatment (Secondary Objective)
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Collaborators:
Azienda Ospedaliera "Sant'Andrea" Azienda Ospedaliero, Universitaria Pisana Istituto Auxologico Italiano Mauriziano Umberto I Hospital